These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32031759)

  • 1. Recent Advances in Nanotheranostics for Treat-to-Target of Rheumatoid Arthritis.
    Wang S; Lv J; Meng S; Tang J; Nie L
    Adv Healthc Mater; 2020 Mar; 9(6):e1901541. PubMed ID: 32031759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treat-to-target in rheumatoid arthritis: Evaluating the patient perspective using the Patient Opinion Real-Time Anonymous Liaison system: The RA T2T PORTAL study.
    Benham H; Rutherford M; Kirby S; Stebbings S; White D; Sim D; Harrison A
    Int J Rheum Dis; 2019 May; 22(5):874-879. PubMed ID: 30793870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).
    Ramiro S; Landewé RB; van der Heijde D; Sepriano A; FitzGerald O; Ostergaard M; Homik J; Elkayam O; Thorne JC; Larche M; Ferraccioli G; Backhaus M; Boire G; Combe B; Schaeverbeke T; Saraux A; Dougados M; Rossini M; Govoni M; Sinigaglia L; Cantagrel AG; Allaart CF; Barnabe C; Bingham CO; Tak PP; van Schaardenburg D; Hammer HB; Dadashova R; Hutchings E; Paschke J; Maksymowych WP
    Ann Rheum Dis; 2020 Apr; 79(4):453-459. PubMed ID: 32094157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A patient-centered knowledge translation tool for treat-to-target strategy in rheumatoid arthritis: Patient and rheumatologist perspectives.
    Benham H; Chiu H; Tesiram J; Mehdi A; Landsberg P; Grosman S; Harrison A; Nash P; Thomas R; Langbecker D; Van Driel M
    Int J Rheum Dis; 2021 Mar; 24(3):355-363. PubMed ID: 33470051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategies are more important than drugs in the management of rheumatoid arthritis.
    Drosos AA; Pelechas E; Voulgari PV
    Clin Rheumatol; 2020 Apr; 39(4):1363-1368. PubMed ID: 32088801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort.
    Sepriano A; Ramiro S; FitzGerald O; Østergaard M; Homik J; van der Heijde D; Elkayam O; Thorne JC; Larché MJ; Ferraccioli G; Backhaus M; Burmester GR; Boire G; Combe B; Schaeverbeke T; Saraux A; Dougados M; Rossini M; Govoni M; Sinigaglia L; Cantagrel A; Barnabe C; Bingham CO; Tak PP; van Schaardenburg D; Hammer HB; Paschke J; Dadashova R; Hutchings E; Landewé R; Maksymowych WP
    J Rheumatol; 2020 Jun; 47(6):809-819. PubMed ID: 31523049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of rheumatoid arthritis in clinical practice using treat-to-target strategy: Where do we stand in the multi-ethnic Malaysia population?
    Tan BE; Lim AL; Kan SL; Lim CH; Ng YF; Tng SLC; Hassin NS; Chandran L; Hamid NA; Lee YYL
    Rheumatol Int; 2017 Jun; 37(6):905-913. PubMed ID: 28389855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in implementing treat-to-target in rheumatoid arthritis: a perspective from Brazilian rheumatologists.
    Kakehasi AM; Duarte ALBP; Brenol CV; Domiciano DS; Laurindo IMM; Bonfiglioli KR; da Mota LMH; Buch MH; de Almeida Macêdo E; Xavier RM
    Adv Rheumatol; 2024 Aug; 64(1):63. PubMed ID: 39187901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicine - advantages for their use in rheumatoid arthritis theranostics.
    Xiao S; Tang Y; Lv Z; Lin Y; Chen L
    J Control Release; 2019 Dec; 316():302-316. PubMed ID: 31715278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanotherapeutics relieve rheumatoid arthritis.
    Yang M; Feng X; Ding J; Chang F; Chen X
    J Control Release; 2017 Apr; 252():108-124. PubMed ID: 28257989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comorbidities-Their role in the treat to target concept for rheumatoid arthritis].
    Krüger K; Kneitz C
    Z Rheumatol; 2019 Jun; 78(5):422-428. PubMed ID: 31049664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine is more than a supporting role in rheumatoid arthritis therapy.
    Han Y; Huang S
    J Control Release; 2023 Apr; 356():142-161. PubMed ID: 36863691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.
    Vermeer M; Kuper HH; Moens HJ; Drossaers-Bakker KW; van der Bijl AE; van Riel PL; van de Laar MA
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1219-26. PubMed ID: 23436821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.
    Steunebrink LM; Vonkeman HE; ten Klooster PM; Hoekstra M; van Riel PL; van de Laar MA
    Clin Rheumatol; 2016 Mar; 35(3):609-15. PubMed ID: 26852313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treat to target strategy in early rheumatoid arthritis versus routine care - A comparative clinical practice study.
    Brinkmann GH; Norvang V; Norli ES; Grøvle L; Haugen AJ; Lexberg ÅS; Rødevand E; Bakland G; Nygaard H; Krøll F; Widding-Hansen IJ; Bjørneboe O; Thunem C; Kvien T; Mjaavatten MD; Lie E
    Semin Arthritis Rheum; 2019 Apr; 48(5):808-814. PubMed ID: 30205983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
    Woodworth TG; den Broeder AA
    Best Pract Res Clin Rheumatol; 2015; 29(4-5):543-9. PubMed ID: 26697765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in the activity of rheumatoid arthritis as the consequence of treat-to-target strategy: eight-year data from 2009 to 2016.
    Xie W; Li J; Zhang X; Li G; Hao Y; Zhao J; Wang L; Sun X; Fan Y; Zhang Z
    Clin Exp Rheumatol; 2018; 36(5):820-828. PubMed ID: 29533754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating rheumatoid arthritis to target: a Canadian patient survey.
    Haraoui B; Bensen W; Thorne C; Wade J; Deamude M; Prince J; Légaré J
    J Clin Rheumatol; 2014 Mar; 20(2):61-7. PubMed ID: 24561407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
    J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan.
    Kaneko Y; Koike T; Oda H; Yamamoto K; Miyasaka N; Harigai M; Yamanaka H; Ishiguro N; Tanaka Y; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):43-9. PubMed ID: 24950169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.